Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate Authors: Raheleh Eftekhari Kenzerki, Mehdi Karamian, Iraj Sharifi, Abbas Pardakhty, Hamidreza Kheiri, Ehsan Salarkia, Alireza Keyhani Published: 2026 ABSTRACT AbstractLeishmaniasis is a neglected tropical disease that urgently requires safer and more effective therapeutic strategies. Rhoifolin (RF), a natural flavonoid with anti-inflammatory and antiparasitic potential, has shown promising biological activities against several infectious diseases. In the present study, the antileishmanial effects of free RF and its niosomal formulation (NRF), alone and in combination with meglumine antimoniate (MA), were investigated against Leishmania major. Niosomes were prepared using Span 40, Tween 40, and cholesterol, resulting in high encapsulation efficiency (90.9%) and a sustained drug-release profile. The antileishmanial activity of RF, NRF, MA, and their combinations against promastigotes was evaluated using both MTT and trypan blue exclusion assays, while anti-amastigote activity was assessed in infected macrophages. NRF exhibited greater efficacy than free RF against both promastigote and amastigote forms of L. major. Combination treatments demonstrated additive interactions (combination index ≈ 1.0) and higher selectivity indices, indicating enhanced efficacy and safety. In addition, treatment with RF, NRF, and their combinations significantly increased LDH release and ROS production in infected macrophages compared with untreated controls. Molecular docking analysis revealed a strong binding affinity of RF toward caspase-3. Furthermore, treatment with RF and NRF significantly modulated apoptosis-related mediators, including increased expression of CASP3, CASP8, and Bax, along with reduced Bcl-2 expression. Immunological analyses also demonstrated macrophage polarization toward the M1 phenotype through upregulation of TNF-α, IFN-γ, IL-12, and iNOS/NO, accompanied by downregulation of IL-10, TGF-β, and ARG1. These immunomodulatory and apoptosis-associated effects were more pronounced in the NRF and NRF + MA groups. Overall, our findings suggest that niosomal RF represents a promising lipid-based delivery system for enhancing the antileishmanial efficacy of RF. The NRF + MA combination may provide a potential therapeutic strategy for improving treatment outcomes and reducing the limitations associated with current therapies for cutaneous leishmaniasis.Keywords: Cutaneous leishmaniasis, Rhoifolin, Niosomes, Apoptosis, Macrophage polarizationSubject terms: Biochemistry, Drug discovery, Immunology Introduction Leishmaniasis, a neglected vector-borne disease affecting humans, encompasses a spectrum of pathological conditions caused by various species of flagellated protozoan parasites within the genus Leishmania, which belongs to the family Trypanosomatidae1,2. Currently, at least 20 Leishmania species are recognized as pathogenic to humans, and their transmission is facilitated by female sandflies1,3. Clinically, leishmaniasis is manifested in three primary forms: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL)4. Among these forms, CL is the most commonly observed and is characterized by the development of skin lesions5. This disease is endemic in more than 100 countries, primarily in tropical and subtropical regions of Asia, Latin America, Africa, and Europe6,7. Globally, more than 1 billion people reside in endemic areas and remain at risk of infection, with an estimated 50,000 to 90,000 new cases of VL and more than 600,000 to 1 million new cases of CL reported annually, resulting in approximately 20,000 to 30,000 deaths each year. Leishmaniasis is classified among the six highest-priority parasitic diseases, following malaria8–10. In Iran, the reported incidence rate in 2019 was 15.8 cases per 100,000 individuals11. Leishmania major is recognized as the predominant etiological agent of CL in the Middle Eastern region2. The contemporary therapeutic approach for leishmaniasis mainly relies on pentavalent antimonials, pharmacological agents that have been used for more than eight decades3,9,12. However, currently proposed therapeutic regimens for CL are frequently associated with numerous adverse effects and substantial costs. Furthermore, the emergence of drug-resistant parasite strains may impair patient responsiveness to these drugs13. The development of new antileishmanial compounds is imperative because of the limitations of existing therapeutic modalities and the significant toxicological effects associated with conventional pharmacotherapies14. Therefore, considerable efforts have been made to identify novel natural remedies derived from botanical sources, including herbal derivatives (flavonoids) and plant extracts, that are effective, safe, non-toxic, and cost-effective for the treatment of such diseases11. Given that plant-derived substances have been used by humans for centuries, the increasing incorporation of herbal products into drug development is not unexpected15. Numerous compounds isolated from plant sources have thus far demonstrated promising antileishmanial activity16. Flavonoids constitute a large group of phenolic secondary metabolites classified within the natural polyphenol family17. Apigenin is among the most abundant flavonoids found in edible plants and in plants used in traditional medicine for the treatment of various disorders18. Furthermore, the role of apigenin in promoting cellular apoptosis has been extensively documented. Strong scientific evidence has demonstrated that flavonoids, particularly apigenin, exhibit significant antileishmanial activity. These effects are primarily mediated through multiple mechanisms, including inhibition of essential parasite enzymes, arrest of cell cycle progression, induction of programmed cell death (apoptosis), and increased production of ROS19–21. Two other prominent flavonoids, quercetin and luteolin, have also been reported to exhibit considerable antileishmanial activity22–24. In addition, it has been demonstrated that the combination of flavonoids with conventional drugs can enhance antileishmanial efficacy while reducing the effective drug concentration25,26. Rhoifolin (RF) (apigenin-7-O-β-neohesperidoside), also known as rhoifoloside, is a well-established tri-substituted flavone belonging to the apigenin family27. RF is a natural compound that exhibits a broad range of biological activities, is a natural compound that exhibits a diverse range of biological activities, notably encompassing anti-cancer properties28. Previous investigations have demonstrated that RF can modulate oxidative stress and regulate pro-inflammatory cytokine levels, suggesting its therapeutic potential in the management of inflammatory disorders29. Moreover, RF has been shown to possess enzyme inhibitory properties that may contribute to its therapeutic efficacy30. Novel drug delivery systems (NDDS) represent a transformative approach in pharmaceutical sciences and are designed to optimize the therapeutic efficacy, safety, and patient compliance of medications by controlling the rate, timing, and site of drug release within the body31. These advanced systems overcome the significant limitations of conventional methods, such as poor solubility, non-specific biodistribution, and rapid clearance32. By enabling targeted delivery to specific cells or tissues, providing sustained release over prolonged periods, and protecting sensitive drug molecules, providing sustained release over days or months, and protecting sensitive drug molecules, NDDS enhance drug performance while minimizing side effects33. The targeted treatment of intracellular bacterial, viral, and protozoal infections is a major challenge for many researchers due to the difficulty of transporting drug compounds across multiple biological membranes34. To overcome this problem, NDDS such as topical niosomes and transfersomes have been used because of their ability to enhance drug permeability through biological bilayers35–39. For instance, niosomal formulations encapsulating natural compounds such as resveratrol have been reported to significantly enhance skin permeation and drug stability40. Despite extensive investigations on flavonoids and NDDS for enhanced and targeted drug delivery, no previous study has evaluated the effects of RF against L. major. Furthermore, to the best of our knowledge, no niosomal formulation of RF has yet been developed. Therefore, the present study was designed to prepare a niosomal formulation of RF and to evaluate the antileishmanial activity of both free RF and NRF against the promastigote and amastigote stages of L. major, either alone or in combination with MA, using in vitro, in silico, and gene expression profiling approaches. Previous studies have demonstrated that related flavonoids exert antileishmanial effects through apoptosis, oxidative stress, and macrophage polarization19–22,24−26. However, no investigation has examined the activity of RF against L. major, and no niosomal formulation of RF has previously been reported. Therefore, the present experimental study was conducted to evaluate the antileishmanial activity of free RF and its newly developed NRF, alone and in combination with MA, against L. major. It was hypothesized that NRF would exhibit enhanced efficacy through improved macrophage-targeted delivery, stronger induction of parasite apoptosis (supported by the predicted high-affinity binding to caspase-3), elevated ROS production, and promotion of the M1 leishmanicidal phenotype, thereby resulting in additive effects when combined with MA. To test this hypothesis, the experimental design included niosome preparation and physicochemical characterization, molecular docking analysis, in vitro anti-promastigote and anti-amastigote assays, cytotoxicity and selectivity index evaluation, gene expression profiling of apoptotic and immunomodulatory markers, ROS measurement, and statistical analysis of combination indices. All experiments were performed in triplicate using untreated controls and MA-treated groups as comparators. The present study represents the first investigation of RF against L. major and the first report describing its niosomal formulation, together with the inaugural development of its niosomal formulation, fills a critical gap in the literature and advances lipid carrier-based strategies for flavonoid-mediated therapy in CL. Materials and methods (A) Niosome preparation Nonionic surfactants (Span® 40 and Tween® 40) were obtained from Fluka (Switzerland). Cholesterol was purchased from Sigma-Aldrich (USA). All organic solvents and other chemicals were supplied by Merck Chemicals (Germany). The niosomal suspensions were prepared using the thin-film hydration method 39. Briefly, Span 40, Tween 40, cholesterol (3.5:3.5:3 molar ratio), and RF (1 mg/mL) were dissolved in chloroform. The organic solvent was evaporated using a rotary evaporator (Heidolph, Germany) at 60 °C, and the resulting dried lipid film was maintained under vacuum overnight to ensure complete removal of residual chloroform. Subsequently, normal saline (NS) was used to hydrate the thin lipid film at 55 °C for 30 min. The resulting lipid vesicles were collected and stored in type I borosilicate glass vials at room temperature overnight and were then refrigerated for subsequent analyses. Microscopic observation, size analysis, and physical stability Niosomes can be classified into large/small unilamellar vesicles (LUVs/SUVs), multilamellar vesicles (MLVs), and multivesicular vesicles (MVVs). The morphology of these vesicles, as well as the aggregation and separation of constituent crystals/droplets/particles, have been characterized employing a light microscope. The size of vesicles (the mean volume diameters; dV50) was analyzed by static laser light scattering technique employing static laser scattering technique (Malvern Mastersizer 2000E, UK). For better evaluation of size distribution of niosomal suspension, the span was calculated by following equation: where dV90, dV10 and dV50 are 90, 10 and 50% of the cumulative volume distribution for RF niosomes, respectively. To investigate the physical stability of the prepared lipid vesicles, size measurement was performed at predetermined time intervals, including 2 weeks, 3 and 6 months. During this period, the niosomes have been stored at refrigerated temperatures. The amount of size change during storage periods was used as a key to physical stability41. Calculating the percentage of encapsulation efficiency (% EE) Due to the lipid-soluble nature of RF, the dialysis method was used to separate free and encapsulated drug. Briefly, one ml of the niosomal suspension was placed in a cellulose acetate dialysis bag (Visking tube, MW cut-off 8 kD) and dialyzed against 200 ml of a water/ethanol mixture (80:20 v/v) for 4 h at 25 °C. UV spectroscopy was used to determine the RF concentration. Niosomal bilayers were disrupted by adding 1 ml of isopropyl alcohol, and the percentage of encapsulation efficiency (% EE) was calculated using the following equation: where Cin and Cout refer to the entrapped (remained in dialysis bag) and free (permeated into dialysate liquid) RF concentrations, respectively. In vitro release study The drug release profile was evaluated using an all-glass Franz diffusion cell equipped with a 37 mL receptor compartment and a cellulose acetate synthetic membrane at 37 °C. Prior to the experiment, the membrane was hydrated overnight in a water/ethanol mixture (50:50 v/v), which was also used as the receptor medium. Samples were collected from the receptor compartment at predetermined time intervals while continuous stirring was maintained. After each sampling, an equal volume of fresh solvent was added to the receptor compartment to maintain sink conditions. The cumulative percentage of RF released over a 4 h period was determined to evaluate the suitability of the RF niosomal formulation for potential topical application. (B) Molecular docking hotspot of valuable residues in the structure of CASP3 was detected by the “Hotspot” server and CASTp v3.0. Measuring open superficial extents on 3-dimensional (3D) structures is essential in advanced experiments. Using Molegro Virtual Docker software (v6.0), pockets were identified on surfaces and in cavities. The 3D structure of RF was obtained from PubChem (CID 5282150). The 3D structure of CASP3 was obtained from the Protein Data Bank (PDB). Molecular docking investigations were completed in Molegro ApS (Aarhus 2.5.0, Denmark). (C) In vitro assay Drugs and reagents RF (CAS No. 17306-46-6) was purchased from Sigma (Germany). MA was obtained from Sanofi-Aventis (France). Drug dilutions were prepared in DMSO at sequential concentrations of 12.5, 25, 50, 100, 200, and 400 µM. Tetrazolium salt (MTT) and DMSO were used for the MTT assay. The permeable fluorescent probe 2′,7′-dichlorofluorescein diacetate was purchased from Sigma. Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were supplied by Biosera (France). Parasite and macrophage culture The standard strain (MHOM/IR/Mash2) of L. major promastigotes was obtained from the Leishmaniasis Research Center (Kerman, Iran). Parasites were cultured in RPMI-1640 medium supplemented with 10% FBS and penicillin–streptomycin antibiotics and were incubated at 25 ± 1 °C. The human monocytic cell line THP-1 was obtained from the Pasteur Institute (Tehran, Iran) and cultured in DMEM supplemented with 10% FBS, penicillin, and 0.5% streptomycin. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂. Differentiation of THP-1 monocytes into macrophage-like cells (MLCs) was induced using phorbol 12-myristate-13-acetate (PMA). Anti-promastigote activity The antileishmanial activity of RF, NRF, MA, and their combinations against L. major promastigotes was evaluated using the MTT assay. Promastigotes in the logarithmic growth phase (1 × 105 parasites/mL) were seeded into 96-well plates and treated with increasing concentrations of the tested compounds. Following incubation for 72 h at 25 ± 1 °C, 10 µL of MTT solution was added to each well, and the plates were further incubated for 3 h. Subsequently, 100 µL of DMSO was added to dissolve the formazan crystals, and optical density (OD) values were measured at 530 nm using a microplate reader. IC50 values were calculated from dose–response curves using SPSS software version 22. In parallel, anti-promastigote activity was confirmed using the trypan blue exclusion assay under identical experimental conditions. IC50 values were calculated based on the percentage of viable (unstained) parasites and were reported alongside the MTT-derived values. Anti-amastigote activity MLCs were cultured on glass microscope slides at a density of 1 × 105 cells/mL and incubated for 24 h at 37 °C in a 5% CO2 atmosphere. Thereafter, macrophages were infected with stationary-phase promastigotes at a parasite-to-cell ratio of 10:1 and incubated for an additional 24 h to allow transformation into the amastigote form. Following infection, various concentrations of RF, NRF, MA, and their combinations (50, 100, 200, and 400 µg/mL) were added, and the cells were incubated for 72 h. The slides were subsequently dried, fixed with methanol, and stained using Wright–Giemsa stain. The IC50 values against intracellular amastigotes were determined by calculating the mean number of amastigotes per 100 macrophages. Cytotoxicity assay To evaluate the cytotoxic impact on MLC, different concentrations (50, 100, 200, and 400 µg/ml) of RF, NRF, MA, and their combination have been introduced to the cells. These have been then incubated for 72 h at 37 °C in a 5% CO2 atmosphere in 96-well plates. Afterward, 10 µL of MTT solution was added to each well, and an additional 3 h of incubation was allowed. After thappears to be, 100 µL of DMSO was included, and the OD was measured at 530 nm employing an ELISA reader. Each concentration was tested in triplicate and compared to to an untreated control group. The drugs’ safety was assessed through the selectivity index (SI), which was determined employing the equation SI = CC50/IC50; an SI above 1 indicates minimal toxicity. LDH release assay in Leishmania-infected macrophages An LDH release assay was performed according to the manufacturer’s instructions to evaluate relative LDH release from Leishmania-infected macrophages following treatment with RF, NRF, MA, and their combinations. After the treatment period, the plates were centrifuged at 400 × g for 5 min, and 100 µL of supernatant from each well was transferred into a new 96-well plate. An equal volume of LDH detection working solution was added, and the plate was incubated for 20–30 min at room temperature in the dark. The reaction was terminated by adding 50 µL of stop solution, and absorbance was measured at 490 nm using a reference wavelength of 620 nm. Background absorbance from culture medium alone was subtracted from all measurements. Relative LDH release was expressed as the ratio of experimental LDH activity to that of the positive control group (infected macrophages treated with 1% Triton X-100 or kit lysis reagent) after subtraction of values obtained from the negative control group (untreated infected macrophages). RT-PCR assay We evaluated the reviewer’s concern by using two independent housekeeping genes and selecting the more stable one for final analysis. Specifically, to assess the effect of drug exposure on gene expression, quantitative real-time PCR (qPCR) was performed to compare the levels of M1 and M2 macrophage-related cytokines (IFN-γ, IL-12p40, iNOS, TGF-β, IL-10, and ARG1) and apoptotic mediators (CASP3, CASP8, cytochrome P450, Bax, and Bcl-2) in intra-macrophage amastigotes. Total RNA was extracted using YTzol Pure RNA reagent (Yektatajhiz, Iran), and RNA concentration and purity were determined with a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized from 1 µg of total RNA using a commercial cDNA synthesis kit (Yektatajhiz, Iran), and qPCR was performed with YTA SYBR Green qPCR MasterMix (Yektatajhiz, Iran). For normalization, we initially tested two housekeeping genes, GAPDH and HPRT, and calculated relative expression using the 2–ΔΔCT method. Both were measured under all experimental conditions, and comparison of their Ct values showed that GAPDH was more stable (lower variability across treatments), so it was selected as the reference gene for the final qPCR analysis, with HPRT used only to confirm the consistency of normalization (Table 1). Table 1The specific primers and reference gene sequences.GeneForward sequence (5′–3′)Reverse sequence (5′–3′)Product size (bp)ARG-1TGATGTTGACGGACTGGACCATCTAATCCTGAGAGTAGCCCT66BaxCCCGAGAGGTCTTTTTCCGACCAGCCCATGATGGTTCTGAT63Bcl-2GGTGGGGTCATGTGTGTGGCGGTTCAGGTACTCAGTCATC63CASP3CATGGAAGCGAATCAATGGACTGTACCAGACCGAGATGTCA59CASP8AGAGTCTGTGCCCAAATCAACTGCTTCTCTCTTTGCTGAA59Cytochrome P450CCCAGGCAGTCAGATCATCTAGCTGCCCCTCAGCTTGA78GAPDHAGGTCGGTGTGAACGGATTTGGGGTCGTTGATGGCAACA95IFN-γACAGCAAGGCGAAAAAGGATGGTGGACCACTCGGATGA106IL-10CTTACTGACTGGCATGAGGAGCAGCTCTAGGAGCATGTGC134IL-12 P40TGGTTTGCCATCGTTTTGCTGACAGGTGAGGTTCACTGTTTC171iNOSACATCGACCCGTCCACAGTACAGAGGGGTAGGCTTGTCTC89TGF-βCCACCTGCAAGACCATCGACCTGGCGAGCCTTAGTTTGGAC112TNF-αCAGGCGGTGCCTATGTCTCCGATCACCCCGAAGTTCAGTA161HPRTTCAGGCAGTATAATCCAAAGATGGTAGTCTGGCTTATATCCAACACTTCG The specific primers and reference gene sequences. ELISA assay To quantify cytokine and apoptotic mediator levels, supernatants were collected from treated and untreated cell culture wells and analyzed using enzyme-linked immunosorbent assay (ELISA). M1 macrophage-associated mediators, including nitric oxide (NO), TNF-α, IFN-γ, and IL-12, as well as M2 macrophage-associated cytokines, including IL-10 and TGF-β, were measured using commercially available ELISA kits (Karmania Pars Gene, Iran). Arg-1 levels were determined using a commercial ELISA kit (MyBioSource, USA). Apoptotic mediators, including CASP3 (MBS040290), CASP8 (MBS260539), cytochrome P450 (MBS705506), Bax (MBS935667), and Bcl-2 (MBS9501407), were quantified using ELISA kits obtained from MyBioSource (USA). All assays were performed according to the manufacturers’ instructions. ROS measurement To measure the average quantity of ROS in L. major intra-macrophage amastigotes, 10⁶ macrophages were treated with IC50 concentrations of RF, NRF, and MA, individually or in combination, and incubated for 72 h. Subsequently, the cells were loaded with 10 µM of a 2′,7′-dichlorofluorescein diacetate (Sigma) permeabilization probe diluted in DMSO and incubated for 25 min at 37 °C in 5% atmospheric CO2. The cells were then rinsed with PBS (pH 7.3). ROS levels were analyzed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). Statistical analyses SPSS v.22 and GraphPad Prism v.10.0 were used for statistical analyses, including paired t-tests and one-way ANOVA, and p-values < 0.05 were considered statistically significant. The selectivity index (SI) for each compound was obtained as the ratio between the cytotoxic concentration for 50% of macrophages (CC50) and the IC50 against intracellular amastigotes, i.e. SI = CC50(macrophages) / IC50(amastigotes). Drug–drug interactions were quantified using the combination index (CI), where CI < 1, CI = 1 and CI > 1 indicate synergistic, additive and antagonistic effects, respectively, with CI calculated according to the Chou–Talalay equation as CI = D1,comb / D1,alone + D2,comb / D2,alone, where D1,alone and D2,alone are the doses of each drug producing a given effect when used individually, and D1,comb and D2,comb are the corresponding doses in combination that yield the same effect level. Results (A) Niosome characteristics Microscopic observation Niosomes containing RF have been examined by optical microscopy, where many round multilamellar vesicles (MLVs) have been observed (Fig. 1). Optical microscopy micrograph of RF niosomes with 10 × 40 magnification. Bar indicates 10 μm scale. Physical stability of niosomes Figure 2 illustrates the physical stability of RF-loaded niosomes during 6 months of storage under refrigerated conditions. The mean volume diameter (dV50) of the niosomes was determined to be 7.1 ± 0.2 μm. Despite this particle size, no evidence of lipid vesicle aggregation was observed, resulting in a narrow size distribution profile. The span value of RF-loaded niosomes (Eq. 1) was calculated to be 1.1, further indicating minimal size variation during both preparation and storage. In addition, no evidence of constituent crystal or particle formation was detected by light microscopy. Size distribution curves of niosomes containing RF during 6 months of storage at 4–8 °C as an indicator of physical stability. Release of RF from niosomes As depicted in Fig. 3, the percentage of RF release was less than 4% due to the lipid-soluble nature of the entrapped molecule and a lag time equal to 30 min. Release profile of RF from prepared niosomes at 37 °C (mean ± SD, n = 3). Encapsulation efficiency percent (EE%) of RF The encapsulation efficiency (EE%) of RF was notably high at 90.90%, using Eq. (1). (B) Molecular docking To investigate the structural basis of CASP3 function, its topological and structural characteristics, including surface cavity architecture, were analyzed. The results demonstrated that CASP3 predominantly adopted a compact conformation containing four distinct cavities (Fig. 4). Identification of these structural features may facilitate the development of targeted therapeutic strategies involving CASP3. The predicted active site consisted of several key interacting residues, including TRP194, ALA197, LEU209, PHE369, and TYR489 (Table 2; Fig. 4C). Molecular docking analysis yielded a MolDock score of − 130.907 kcal/mol, with 40 heavy atoms, an E_intra value of 31.45, and an E_pair value of − 162.36. The predicted binding site was located at X = − 48.52, Y = 8.57, and Z = − 25.83 and involved 34 amino acid residues (Table 2). Docking illustration: (A) CASP3 comprises a central compact domain and 4 cavities. (B) Molecular docking by the Molgro Virtual Docker software. (C) Cast-P, (D) amino acids predicted in pocket formation by the PLIP web tool. Table 2Contribution of the CASP3 residues/molecules.Hydrophobic interactionsIndexResidueAADistanceLigand AtomProtein Atom1135BASP3.29628236822137BLYS3.43627937133140BTHR3.49627037784144BARG3.2562683845Hydrogen bondsIndexResidueAADistance H-ADistance D-ADonor angleDonor atomAcceptor atom1135BASP2.053.02175.496256 [O2]3684 [O2]2140BTHR1.592.30126.136249 [O3]3775 [O2]3140BTHR2.383.18134.203777 [O3]6245 [O3]4143BPHE2.333.14140.086250 [O3]3823 [O2]5156BLYS1.702.67170.406246 [O3]4032 [O2]6156BLYS1.952.84150.806248 [O3]4032 [O2]7158BPHE3.234.09142.194070 [Nam]6248 [O3]8158BPHE2.473.13124.886252 [O3]4073 [O2]Salt bridgesIndexResidueAADistanceLigand groupLigand atoms1137BLYS5.20Carboxylate6245, 6243 Contribution of the CASP3 residues/molecules. Table 3Comparison of the effects of different concentrations of Rhoifolin (RF), niosomal form of Rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) on the average number of intra-macrophage amastigotes compared to the untreated control group (UC).Concentration (µg/mL)Mean amastigotes ± SD (UC)Mean amastigotes ± SD (FN)Mean amastigotes ± SD (MA)Mean amastigotes ± SD (RF)Mean amastigotes ± SD (NRF)Mean amastigotes ± SD (RF + MA)Mean amastigotes ± SD (NRF + MA)0.059.6 ± 2.8------12.5-59.6 ± 2.850.7 ± 3.5*48.6 ± 3.1*40.3 ± 2.0*40.3 ± 1.6*34.2 ± 1.2*25-56.3 ± 1.445.1 ± 2.1*36.2 ± 1.6*31.2 ± 1.6*34.6 ± 2.2*30.1 ± 1.1*50-52.1 ± 1.038.7 ± 3.9*30.3 ± 2.7*25.3 ± 1.7*28.3 ± 1.0*20.1 ± 2.1*100-48.6 ± 0.932.6 ± 4.1*24.3 ± 3.0*12.3 ± 2.1*14.3 ± 1.2*7.3 ± 0.6*200-45.4 ± 1.318.6 ± 1.2*10.2 ± 1.8*5.6 ± 1.3*0 ± 0*0 ± 0*400-42.1 ± 0.80 ± 0*0 ± 0*0 ± 0*0 ± 0*0 ± 0** p < 0.001 compared to Untreated Control (UC). Comparison of the effects of different concentrations of Rhoifolin (RF), niosomal form of Rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) on the average number of intra-macrophage amastigotes compared to the untreated control group (UC). * p < 0.001 compared to Untreated Control (UC). In vitro investigations Anti-promastigote functions The antileishmanial activity of RF, NRF, MA, and their combinations against L. major promastigotes was evaluated using both the MTT assay and the trypan blue exclusion assay. As shown in Fig. 5A, treatment with the tested compounds resulted in a concentration-dependent reduction in promastigote viability in the MTT assay. Similar findings were observed in the trypan blue exclusion assay (Fig. 5B), confirming the concentration-dependent decrease in promastigote viability. The IC50 values for anti-promastigote activity determined by both the MTT and trypan blue methods are summarized in Table 4. Effects of free niosome (FN), Rhoifolin (RF), niosomal Rhoifolin (NRF), meglumine antimoniate (MA), and their combinations (RF + MA and NRF + MA) on the viability of L. major promastigotes at different concentrations. Figure 5A shows the results of the MTT assay, while Fig. 5B presents the results of the trypan blue exclusion assay. Data are presented as mean ± SD. Table 4Evaluation of IC50 values for rhoifolin (RF), niosomal form of rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) against promastigotes and amastigotes of L. major compared to MA, and CC50 values of drugs on macrophages to calculate the selectivity index (SI) and combination index (CI).DrugsAmastigotePromastigoteMacrophageSICIIC50 ± SD (µg/mL)P-valueIC50 ± SD (µg/mL) MTTIC50 ± SD (µg/mL) TBP-valueCC50 (µg/mL)MA103.73NR324.71301.97NR593.35.72-RF50.93P < 0.001122.27111.48P < 0.001322.46.33-NRF33.38P < 0.00170.7868.67P < 0.001243.27.29-RF + MA40.37P < 0.00176.6072.68P < 0.001340.78.441.1NRF + MA27.69P < 0.00163.1561.85P < 0.001252.09.101.0NR: Not related. Evaluation of IC50 values for rhoifolin (RF), niosomal form of rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) against promastigotes and amastigotes of L. major compared to MA, and CC50 values of drugs on macrophages to calculate the selectivity index (SI) and combination index (CI). NR: Not related. Anti-amastigote assessment In this study, different concentrations of RF, NRF, MA, and especially their combinations, significantly inhibited the proliferation of amastigotes within macrophages compared to the control group (p < 0.001) (Table 3). Cytotoxic effects and combination index The cytotoxicity and therapeutic potential of RF, NRF, MA, and their combinations were evaluated by assessing the selectivity index (SI). Additionally, the combination index (CI) values were calculated as 1.1 and 1.0 for RF + MA and NRF + MA, respectively, indicating an additive interaction between the compounds. LDH release Treatment with RF, NRF, MA, and their combinations significantly affected LDH release in Leishmania-infected macrophages compared with the untreated control group. Among the treated groups, NRF and NRF + MA exhibited the highest levels of LDH release, indicating enhanced membrane damage and increased cytotoxic effects in infected macrophages (Fig. 6). LDH release in Leishmania-infected macrophages treated with RF, NRF, MA, RFMA, and NRFMA compared with untreated control (UC). Data are presented as mean ± SD. Statistical significance is indicated as p < 0.05, p < 0.01, p < 0.001, and p < 0.0001. Apoptotic mediators A significant increase in the apoptotic mediators CASP3 (Fig. 7A, B), CASP8 (Fig. 7C, D), and Bax (Figs. 7G and I and 8A and B) was observed compared to the untreated control group (p < 0.001). In addition, combination treatments (RF + MA and NRF + MA) produced significantly greater effects than RF or NRF alone (p < 0.001). Conversely, a significant decrease was detected in the anti-apoptotic mediator Bcl-2 (Figs. 7H and J and 8C and D) and in cytochrome P450 reductase (CP450R) (Fig. 7E, F) compared to the control group (p < 0.001). These inhibitory effects were also more pronounced in the combination treatment groups than in the monotherapy groups. The effects of Rhoifolin (RF), niosomal Rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) on intra-macrophages amastigotes in comparison to the untreated control group (UC), on gene expression and mean level of apoptotic mediator, including A, B: CASP3; C, D: CASP8; E, F: cytochrome P450 reductase (CP450R); G, I: Bax, and H, J: Bcl-2. Bars are standard deviation *p < 0.05, **p < 0.01,***p < 0.001 and **** p < 0.0001) The effects of Rhoifolin (RF), niosomal Rhoifolin (NRF), meglumine antimoniate (MA) alone, and their combinations (RF + MA and NRF + MA) on intra-macrophages amastigotes in comparison to the untreated control group (UC), on gene expression and mean level of apoptotic mediator, including A, B: Bax; C, D: Bcl-2; Bars are standard deviation *p < 0.05, **p < 0.01,***p < 0.001 and **** p < 0.0001) ROS production Treatment of intra-macrophage amastigotes with RF, NRF, MA, and especially their combinations, resulted in a significant increase in ROS production compared to the untreated control group (p < 0.001) (Fig. 9). Effect of Rhoifolin (RF), niosomal form of Rhoifolin (NRF), meglumine antimoniate (MA) alone, and their mixture (RF + MA and NRF + MA) on percentage of ROS production in intra-macrophages amastigotes compared to the untreated control (UC) group. Data are presented as mean ± standard deviation. (*p < 0.05, **p < 0.01,***p < 0.001 and **** p < 0.0001) M1 and M2 type cytokines and ARG1 The effects of RF, NRF, MA, and their combinations on the gene expression and protein levels of M1- and M2-associated mediators in intra-macrophage amastigotes are shown in Figs. 10 and 11. Treatment with RF, NRF, or MA significantly increased both the gene expression and mean protein levels of M1-associated mediators, including iNOS and nitric oxide (NO) (Fig. 10A, B), IL-12 (Fig. 10C, D), TNF-α (Fig. 10E, F), and IFN-γ (Fig. 10G, H), compared with the untreated control (UC) group (p < 0.001). Moreover, combination treatments (RF + MA and NRF + MA) induced significantly greater increases in these M1-related mediators than monotherapies (p < 0.001). In contrast, treatment with RF, NRF, MA, and particularly their combinations significantly reduced both the gene expression and mean protein levels of M2-associated mediators, including IL-10 (Fig. 11A, B), TGF-β (Fig. 11C, D), and ARG1 (Fig. 11E, F), compared with the UC group (p < 0.001). The suppressive effects on M2-related mediators were more pronounced in the combination treatment groups. Effects of Rhoifolin (RF), its niosomal form (NRF), meglumine antimoniate (MA), and their combinations (RF + MA and NRF + MA) on intra-macrophage amastigotes compared to the untreated control (UC) group. The panels show gene expression and mean levels of macrophage-related cytokines: M1 markers – A, B: iNOS and nitric oxide (NO); C, D: IL-12; E, F: TNF-α; G, H: IFN-γ. Data are presented as mean ± standard deviation. *p < 0.05, **p < 0.01,***p < 0.001 and **** p < 0.0001) Effects of Rhoifolin (RF), its niosomal form (NRF), meglumine antimoniate (MA), and their combinations (RF + MA and NRF + MA) on intra-macrophage amastigotes compared to the untreated control (UC) group. The panels show gene expression and mean levels of macrophage-related cytokines M2 markers – A, B: IL-10; C, D: TGF-β; and E, F: arginase 1 (ARG1). Data are presented as mean ± standard deviation. *p < 0.05, **p < 0.01,***p < 0.001 and **** p < 0.0001) Discussion The global challenge of leishmaniasis, exacerbated by the limited efficacy and severe toxicity of current chemotherapies, necessitates the exploration of novel therapeutic strategies. The present study investigated the antileishmanial potential of RF, both in its free form and within a NRF, against L. major. Our results suggest that RF combats Leishmania parasites through three interconnected mechanisms: potent modulation of the host macrophage immune response, direct induction of parasite apoptosis, and the generation of overwhelming oxidative stress. The therapeutic potential of many flavonoids, including RF, is often hampered by poor aqueous solubility, low bioavailability, and rapid metabolism42. Therefore, the development of NDDSs such as niosomes is crucial for overcoming these challenges and realizing the full potential of complex modern therapeutics, including natural biologics (such as flavonoids), gene therapies, and personalized medicine, thereby ushering in a new era of precision treatment43. For effective in vitro/in vivo delivery of antileishmanial compounds such as amphotericin B44, artemether38, dapsone/silver45 and zirconium/tioxolone46 niosomal formulations have been prepared and studied. Our niosomal RF formulation showed high encapsulation efficiency (90.90%), sustained-release profile and excellent physical stability. On the other hand, NDDS such as niosomes are passively targeted by macrophages—the parasite’s sanctuary—through natural phagocytosis47. This maximizes drug concentration precisely where it is needed most, enhancing efficacy while minimizing systemic exposure and off-target toxicity48. This targeted delivery, along with the protection of the encapsulated drug from premature degradation, directly contributed to the remarkable increase in the selectivity index (SI) to 9.10 for the NRF + MA formulation. A high SI signifies a wider therapeutic window and a superior safety profile, which is of great importance for the development of any new drug for clinical use, especially in resource-limited areas where leishmaniasis is most prevalent. The NRF + MA and NRF formulation showed the least IC50 values against promastigotes and amastigotes of L. major (Table 4), probably by better penetration of encapsulated material through biological membranes of the parasite species49. The cornerstone of the host defense against Leishmania is the functional state of the macrophage. This parasite is a master manipulator, actively polarizing macrophages toward an M2 “alternatively activated” phenotype. This creates an immunosuppressive milieu that is ideal for parasite survival and replication through the secretion of cytokines such as IL-10 and TGF-β50. Our results indicate that RF and NRF can reverse this process, polarizing macrophages towards the classically activated M1 phenotype, which is essential for parasite clearance. This is explained by the significant increase in key pro-inflammatory cytokines, including interferon-gamma (IFN-γ), interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-α), and nitric oxide (NO). IFN-γ, in particular, is the principal activating cytokine for macrophages, triggering the expression of inducible nitric oxide synthase (iNOS), which in turn produces the potent leishmanicidal molecule nitric oxide (NO)51. By simultaneously suppressing M2-related cytokines, RF effectively eliminates the parasite’s protective niche and restores the innate ability of macrophages to eliminate intracellular amastigotes. This immunomodulatory effect is enhanced by the significant inhibition of Arginase-1 (ARG1). The competition between iNOS and ARG1 for their common substrate, L-arginine, is a central battlefield in the host-parasite interaction43. Leishmania parasites actively upregulate host cell ARG1 to divert L-arginine away from NO production and towards the synthesis of polyamines, which are essential for parasite proliferation52,53. The inhibition of ARG1 by RF represents a sophisticated therapeutic intervention; it simultaneously “starves” the parasite of essential metabolites while restoring the macrophage’s primary killing mechanism. This dual-action property is a hallmark of several effective natural anti-leishmanial compounds, including other flavonoids like fisetin and luteolin54, which suggests RF is a potent modulating agent at this metabolic checkpoint. Recent studies have emphasized that targeting host cell metabolic pathways hijacked by the parasite is a promising strategy to circumvent conventional drug resistance mechanisms55. The second major mechanism identified is the direct induction of programmed cell death (apoptosis) within the parasite. Inducing apoptosis is a far superior therapeutic outcome compared to necrosis, as it ensures the silent removal of parasites without triggering the excessive inflammation that leads to tissue damage and the characteristic ulceration of cutaneous leishmaniasis56. Our in silico analysis predicted a high binding affinity of RF for Caspase-3, a key executioner in the apoptotic cascade. This prediction was confirmed by our experimental data, which showed a significant increase in the expression of pro-apoptotic proteins (CASP3, CASP8, Bax) and a concomitant decrease in the anti-apoptotic molecule Bcl-2. The shifting of the Bax/Bcl-2 ratio towards a pro-apoptotic state is a definitive indicator of mitochondria-mediated apoptosis57. This intrinsic pathway is often triggered by cellular stress, including oxidative damage to the mitochondria, which leads to the release of cytochrome c and subsequent caspase activation57. Apigenin, the aglycone of Rhoifolin, has been reported to induce a similar apoptotic phenotype in Leishmania amazonensis19. Therefore, RF likely acts through this pathway after being metabolized to its aglycone form inside the cell. Other flavonoids, such as luteolin and kaempferol, have also been reported to activate apoptosis in Leishmania species by targeting mitochondrial integrity and enhancing ROS production58. The generation of reactive oxygen species (ROS) was the third mechanism identified and is the linchpin connecting the other two. While macrophages naturally produce an oxidative burst upon infection, Leishmania has evolved a sophisticated antioxidant system (e.g., trypanothione reductase) to neutralize this threat59. Our observations suggest that RF and NRF disrupt this defense by inducing a secondary, unsustainable wave of ROS, pushing the parasite beyond its homeostatic threshold. This increase in ROS is not an isolated event and is intricately linked to apoptosis. The oxidative damage inflicted upon the parasite’s single mitochondrion is a primary trigger for the intrinsic apoptotic pathway60. Therefore, ROS production by RF may act both as a direct lethal agent and as a signaling molecule that initiates a self-destructive sequence in the parasite. The ability of RF to disrupt the redox balance of Leishmania is similar to the effects observed with other flavonoids, such as quercetin and epigallocatechin gallate (EGCG), which have shown similar ROS-mediated antileishmanial activity61,62. There is a growing body of evidence demonstrating that many natural products exert their anti-parasitic effects by disrupting the pathogen’s redox balance63. Combination therapy is increasingly recognized as a viable strategy to enhance treatment efficacy, reduce toxicity, and mitigate drug resistance in leishmaniasis64,65. The additive effect observed between NRF and MA underscores the potential of combining natural compounds with conventional drugs. The NRF + MA combination significantly reduced the IC50 values against both promastigote and amastigote stages, indicating enhanced leishmanicidal activity. The combination also exhibited lower cytotoxicity and a higher selectivity index (SI), suggesting improved safety for in vivo applications. Similar synergistic effects have been reported with other flavonoid-drug combinations. For instance, naringenin combined with miltefosine exhibited enhanced antileishmanial activity against L. amazonensis66, while the combination of rutin and biogenic silver nanoparticles showed synergistic effects67. This highlights the potential of NRF + MA as a safer and more effective therapeutic option for leishmaniasis. When the IC50 and selectivity index (SI) of our niosomal formulations are compared directly with benchmark flavonoids, a clear quantitative landscape emerges. Quercetin, the most extensively studied flavonol, exhibits potent activity against L. amazonensis amastigotes with IC50 values as low as 3.4 µM and an SI of 16.8, while against L. major it achieves an EC50 of 0.85 µM with an SI of approximately 1062,68. Epigallocatechin‑3‑gallate (EGCG) shows an even more striking selectivity, with an IC50 of 3.4‑3.7 µM against L. braziliensis amastigotes and an SI exceeding 100 due to very low macrophage cytotoxicity (CC50 ≈ 384‑436 µM)69. Apigenin and luteolin, structurally related to rhoifolin, display IC50 values in the range of 31‑40 µg/mL against promastigotes and SI values of 11‑25 in active fractions70,71. Our free rhoifolin (RF) shows an amastigote IC50 of 50.93 µg/mL (SI = 6.33), which is less potent than these benchmarks. However, niosomal encapsulation (NRF) improves the IC50 to 33.38 µg/mL and the SI to 7.29. The critical finding is the NRF + MA combination: it achieves an amastigote IC50 of 27.69 µg/mL and an SI of 9.10, representing a 1.8‑fold improvement in potency and a 1.4‑fold improvement in selectivity compared to free RF. While this SI remains below that of quercetin (SI ≈ 10‑16.8) and far below that of EGCG (SI > 100), it surpasses free MA (SI = 5.72) and approaches the range of apigenin‑containing fractions. Thus, the advantage of NRF + MA is not that it outperforms the most potent isolated flavonoids, but that it demonstrates that a moderate‑potency flavonoid (rhoifolin) can be elevated through niosomal delivery and additive combination with meglumine antimoniate to reach a therapeutically relevant window (IC50 < 30 µg/mL, SI > 9). This provides a practical, low‑toxicity strategy that leverages an approved drug (MA) and a simple lipid carrier, offering a viable pathway for clinical translation where ultra‑high SI flavonoids may face formulation or bioavailability challenges. Conclusion Significant antileishmanial activity of RF and its niosomal formulation was observed against both promastigote and amastigote forms of Leishmania major. The NRF demonstrated greater efficacy, particularly when combined with MA. These effects appear to be associated with the upregulation of pro-apoptotic genes, suppression of anti-apoptotic markers, modulation of the immune response toward M1 macrophage polarization, and induction of ROS production. The high encapsulation efficiency and sustained-release profile of NRF highlight its potential to overcome the pharmacokinetic limitations commonly associated with flavonoids, thereby presenting a promising platform for future antileishmanial therapies. Future perspectives include advancing the NRF + MA formulation to preclinical animal models for the evaluation of topical applications in CL, optimizing dosage regimens to further minimize toxicity, and ultimately conducting clinical trials in endemic regions to validate its efficacy and safety in humans. Acknowledgements The authors want to thank the Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran employees for their assistance in conductingthis study. Author contributions REK, MK and IS (original draft preparation, supervision), AP (preparation niosomes), HK (analysis data and validation), REK, ES and AK (methodologist and collected the data). All authors read and approved the final paper. Funding This project was supported by the Zanjan University of Medical Sciences, Zanjan, Iran (Grant No. 5745). Data availability The datasets used and analyzed during the current study are available from the corresponding author. Competing interests The authors declare no competing interests. Ethical approval The present study was approved by the Research Ethics Committees of Biosafety & Laboratory, Zanjan University of Medical Sciences, Zanjan, Iran (Approval ID. IR.ZUMS.BLC.1402.042). Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Mehdi Karamian, Email: karamianm@yahoo.com. Iraj Sharifi, Email: iraj.sharifi@yahoo.com. References Associated Data Data Availability Statement The datasets used and analyzed during the current study are available from the corresponding author.